HER2 testing

Current status and future directions

Edith A. Perez, Javier Cortés, Ana Maria Gonzalez-Angulo, John M S Bartlett

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Accurate determination of human epidermal growth factor receptor 2 (HER2) status is critical for optimizing breast cancer outcomes. In 2007, the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) developed guidelines for HER2 testing to reduce inaccuracy. However, current ASCO/CAP criteria may restrict access to HER2-targeted therapy for some patient groups who would derive a clear clinical benefit. ASCO/CAP are currently reviewing their guidelines to further optimize HER2 testing and include emerging techniques. Guidelines are critical for optimizing care, as is ongoing research into techniques that accurately and reproducibly assess HER2 status.

Original languageEnglish (US)
Pages (from-to)276-284
Number of pages9
JournalCancer Treatment Reviews
Volume40
Issue number2
DOIs
StatePublished - Mar 2014

Fingerprint

Medical Oncology
Guidelines
Critical Care
Research Design
Direction compound
human ERBB2 protein
Breast Neoplasms
Pathologists
Therapeutics

Keywords

  • American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines
  • Human epidermal growth factor receptor 2 (HER2) testing
  • Immunohistochemistry
  • In situ hybridization
  • Variability

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Perez, E. A., Cortés, J., Gonzalez-Angulo, A. M., & Bartlett, J. M. S. (2014). HER2 testing: Current status and future directions. Cancer Treatment Reviews, 40(2), 276-284. https://doi.org/10.1016/j.ctrv.2013.09.001

HER2 testing : Current status and future directions. / Perez, Edith A.; Cortés, Javier; Gonzalez-Angulo, Ana Maria; Bartlett, John M S.

In: Cancer Treatment Reviews, Vol. 40, No. 2, 03.2014, p. 276-284.

Research output: Contribution to journalArticle

Perez, EA, Cortés, J, Gonzalez-Angulo, AM & Bartlett, JMS 2014, 'HER2 testing: Current status and future directions', Cancer Treatment Reviews, vol. 40, no. 2, pp. 276-284. https://doi.org/10.1016/j.ctrv.2013.09.001
Perez EA, Cortés J, Gonzalez-Angulo AM, Bartlett JMS. HER2 testing: Current status and future directions. Cancer Treatment Reviews. 2014 Mar;40(2):276-284. https://doi.org/10.1016/j.ctrv.2013.09.001
Perez, Edith A. ; Cortés, Javier ; Gonzalez-Angulo, Ana Maria ; Bartlett, John M S. / HER2 testing : Current status and future directions. In: Cancer Treatment Reviews. 2014 ; Vol. 40, No. 2. pp. 276-284.
@article{02c4e60d9ce3425a89025b434cf40e3b,
title = "HER2 testing: Current status and future directions",
abstract = "Accurate determination of human epidermal growth factor receptor 2 (HER2) status is critical for optimizing breast cancer outcomes. In 2007, the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) developed guidelines for HER2 testing to reduce inaccuracy. However, current ASCO/CAP criteria may restrict access to HER2-targeted therapy for some patient groups who would derive a clear clinical benefit. ASCO/CAP are currently reviewing their guidelines to further optimize HER2 testing and include emerging techniques. Guidelines are critical for optimizing care, as is ongoing research into techniques that accurately and reproducibly assess HER2 status.",
keywords = "American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines, Human epidermal growth factor receptor 2 (HER2) testing, Immunohistochemistry, In situ hybridization, Variability",
author = "Perez, {Edith A.} and Javier Cort{\'e}s and Gonzalez-Angulo, {Ana Maria} and Bartlett, {John M S}",
year = "2014",
month = "3",
doi = "10.1016/j.ctrv.2013.09.001",
language = "English (US)",
volume = "40",
pages = "276--284",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - HER2 testing

T2 - Current status and future directions

AU - Perez, Edith A.

AU - Cortés, Javier

AU - Gonzalez-Angulo, Ana Maria

AU - Bartlett, John M S

PY - 2014/3

Y1 - 2014/3

N2 - Accurate determination of human epidermal growth factor receptor 2 (HER2) status is critical for optimizing breast cancer outcomes. In 2007, the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) developed guidelines for HER2 testing to reduce inaccuracy. However, current ASCO/CAP criteria may restrict access to HER2-targeted therapy for some patient groups who would derive a clear clinical benefit. ASCO/CAP are currently reviewing their guidelines to further optimize HER2 testing and include emerging techniques. Guidelines are critical for optimizing care, as is ongoing research into techniques that accurately and reproducibly assess HER2 status.

AB - Accurate determination of human epidermal growth factor receptor 2 (HER2) status is critical for optimizing breast cancer outcomes. In 2007, the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) developed guidelines for HER2 testing to reduce inaccuracy. However, current ASCO/CAP criteria may restrict access to HER2-targeted therapy for some patient groups who would derive a clear clinical benefit. ASCO/CAP are currently reviewing their guidelines to further optimize HER2 testing and include emerging techniques. Guidelines are critical for optimizing care, as is ongoing research into techniques that accurately and reproducibly assess HER2 status.

KW - American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines

KW - Human epidermal growth factor receptor 2 (HER2) testing

KW - Immunohistochemistry

KW - In situ hybridization

KW - Variability

UR - http://www.scopus.com/inward/record.url?scp=84888293503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888293503&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2013.09.001

DO - 10.1016/j.ctrv.2013.09.001

M3 - Article

VL - 40

SP - 276

EP - 284

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 2

ER -